Skip to main content
Equibles
OSTX logo

OSTX · OS Therapies Inc · Metrics

Track OSTX — free

Use OSTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OSTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.26 -0.01 (-0.79%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$58.58M
Shares
46.13M
Volume · Oct 20 319.82K Avg daily vol (3M) 581.18K

OSTX metrics

53 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.27
Market cap
$58.58M

Price action

20 metrics
Price change (1W)
-18.6%
Price change (30D)
-27.0%
Price change (3M)
-15.9%
Price change (6M)
-8.0%
Price change (YTD)
-9.3%
Price change (1Y)
-31.4%
Trailing year
Price change (5Y)
—
52-week high
$2.24
52-week low
$1.16
Change from 52-week high
-43.3%
Change from 52-week low
+9.5%
Annualized volatility
74.6%
Annualized volatility (3M)
57.0%
Beta
1.8
RSI (14D)
28.3
Price vs SMA 50
-22.0%
Price vs SMA 200
-19.3%
Avg volume (3M)
581,166
Relative volume
1.2
Average dollar volume
$943,335

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
46.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-64.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$37.61M
Net income (TTM)
−$39.37M
Trailing 12 months
Diluted EPS (TTM)
$-1.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.16

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+74.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-397.8%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$205,035
Total assets
$9.90M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.53M
Capital expenditures (TTM)
$466,423
R&D (TTM)
$25.98M
SG&A (TTM)
—
Stock compensation (TTM)
$5.19M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
0
Institutional ownership
6.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.6%
Private-fund adviser ownership
1.4%
Active holders' share change QoQ
-33.6%
Holder tenure
3.7
Price vs estimated holder cost
+1.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.4%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1795091 CUSIP 68764Y207 13F (30d) 5 filings 4 filers Visit website Investor relations